Notch1 transcriptional complex (NTC)

The Notch1 transcriptional complex (NTC) is the primary nuclear effector of the Notch1 signaling pathway, a highly conserved mechanism for cell-to-cell communication (PMID: 19114024). The complex is formed when the Notch1 intracellular domain (NICD1), released from the plasma membrane via gamma-secretase cleavage, translocates to the nucleus and binds to the DNA-binding protein RBPJ (also known as CSL) and a co-activator of the Mastermind-like (MAML) family (UniProt P46531). This assembly displaces corepressors and recruits histone acetyltransferases to initiate the transcription of target genes such as HES1 and MYC, which are vital for regulating cell differentiation and survival (PMID: 15472075). In many malignancies, particularly T-cell acute lymphoblastic leukemia (T-ALL), gain-of-function mutations in Notch1 lead to the constitutive formation of this complex, driving uncontrolled cellular proliferation. Therapeutic interventions include gamma-secretase inhibitors (GSIs) that block NICD1 release and novel small molecules like CB-103 that directly inhibit the assembly of the transcriptional complex to overcome GSI resistance (PMID: 32066954).

Other names

NICD1/RBPJ/MAML complexNotch1/CSL/MAML complexNotch1 transcriptional activation complexNotch1/RBPJ/MAML1 complex

Inhibition of the gamma-secretase enzyme to prevent the proteolytic release of the Notch1 intracellular domain (NICD1), or direct pharmacological disruption of the protein-protein interactions between NICD1, the DNA-binding protein RBPJ, and the co-activator MAML within the nucleus (PMID: 32066954).